KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

GoodRx Holdings (GDRX) EBITDA (2019 - 2025)

Historic EBITDA for GoodRx Holdings (GDRX) over the last 7 years, with Q3 2025 value amounting to $14.6 million.

  • GoodRx Holdings' EBITDA fell 2835.79% to $14.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.0 million, marking a year-over-year increase of 18248.69%. This contributed to the annual value of $70.3 million for FY2024, which is 41677.4% up from last year.
  • According to the latest figures from Q3 2025, GoodRx Holdings' EBITDA is $14.6 million, which was down 2835.79% from $26.8 million recorded in Q2 2025.
  • In the past 5 years, GoodRx Holdings' EBITDA registered a high of $26.8 million during Q2 2025, and its lowest value of -$38.3 million during Q3 2023.
  • For the 5-year period, GoodRx Holdings' EBITDA averaged around $6.3 million, with its median value being $11.3 million (2023).
  • Within the past 5 years, the most significant YoY rise in GoodRx Holdings' EBITDA was 55238.45% (2023), while the steepest drop was 115284.97% (2023).
  • Quarter analysis of 5 years shows GoodRx Holdings' EBITDA stood at $11.8 million in 2021, then crashed by 85.22% to $1.7 million in 2022, then tumbled by 1152.85% to -$18.3 million in 2023, then surged by 199.41% to $18.2 million in 2024, then dropped by 19.58% to $14.6 million in 2025.
  • Its EBITDA was $14.6 million in Q3 2025, compared to $26.8 million in Q2 2025 and $23.4 million in Q1 2025.